When the U.S. Food and Drug Administration (FDA) approved the drug aducanumab (Aduhelm) for the treatment of Alzheimer’s disease in June, the news was greeted with a considerable mix of responses—from celebratory optimism for the first new Alzheimer’s drug in nearly 20 years to frustration and vocal disagreement with the …